Ozempic called the CEO of the surprise starting with Novo’s outgoing groups

[ad_1]

When Novo Nordisk A / S CEO Lars Frugensard Jorgensen, Helge Lund, a video call, which is a video call to a team, was waiting for an ordinary catch.

Instead, Jorgensen says Lund should be able to go effectively.

In the last year, Wegovy’s obesity shooting increases the failures and competition in the tests of 53% in the manufacturer’s share Eli lilli & CO, NOVO controls, the Board informed the Board that the company’s management was dissatisfied.

Thus, Novo, Novo, Jorgensen, who brought one of the largest medicinal franchises in the market in the last ten years, brought 26 billion to $ 26 billion billion to a crazy and cultural phenomenon of the market.

“I respect this,” Jorgensen said in 58, in an interview. “I think this is part of the game, so it is not for me to judge the criteria for me.”

The action was a surprise for the market as the executive. Jorgensen said that after a one day after the teams and meetings from each other, they were looking for a new leader for the company that lost the best place in the obesity market of Lund and Novo.

The rear opponent lives with the zepbound with lilly, zepbound, obesity medicationproduceCan pull more pounds than Wegovy. More intense competitions are in cards with Lilly Lilly in the race for a strong and easy obesity pill. Novo’s next generation candidateCagrismaThe existing blockbuster is a stroke based on both the company’s company, both the company, both the company, both the company, also built on the main ingredient.

Novo will look for foreign candidates for foreign directors, as well as foreign directors. The pharmacy has five peos in the century and none of them came from outside the company. Although the analysts were called, Lund has repeatedly said that Novo’s strategy will remain the same, and more nuanced in the interview.

Novo’s game plan must “develop and fit into the market and environment and change,” he said. The confusion in Novo for Lund, overlapped with a noise that another company passed: Bp. Last month, BP’s chairman, the energy giant of England, he said he would take a step to fight to gain investor confidence after two major strategy pivotes. Lund, the market price of BP, Lund, was $ 106 billion. It’s about $ 78 billion now.

An unprecedented action

Jorgensen’s progress in Novo is an unprecedented action for a company that is proud of the stability. The sudden, the largest shareholder of the Danish Drammaker, is the reflection of the power of the Novo Nordisk Foundation.

Jorgensen said he was always strong support from the board of Nova before the call with Lund.

“There is no unresolved problem between the management and plaque,” he said. “There are no gaps in the strategic choice, there are no gaps. I all felt strong support for the right opinions of strategic choices and the right opinions of what we do.”

Like many other Novo managers, Jorgensen had a long-term company in the company for a long time. Insulin was always the main product of Novo.

When Jorgensen seized CEO in 2017, the company continued to take only diabetes, but also to the treatment of the fat. Ozempic hit the US market in 2018. In 2021, Jorgensen brought to lose weight in the United States to lose weight, to lose weight.

Nova’s shares were clear that they created a new market for the treatment of strong new drugs. In 2023, the company proved that Wegovy could reduce the risk of heart attack and strokes, and the decisive step for builders to pay for expensive treatments.

Then a year ago, a little less, Nova began to collect the difficulties. The company was to defend prices for ozemptic and wegovy in Congress, a senate questioned by Bernie Sanders during hearing Jorgensen.

Soon, then could not live up to the potential of Cagrisema, Lilly drugs won a clinical victory. Novo, some analysts now have a factor that Lilly said to a competitive shot shot, continued the fight to meet the demand for Wegovy.

“Last year, Novo, when Wegovy did not send the starting doses. I think the market began to create a more permanent change,” said Seigerman analyst with BMO capital markets. “If you have an option to write a prescribe zepbound or wegovy, and they can’t write patient scripts, then you will change this to this job a few times or several times, and you will change this work to Zepbound.”

Sorensen’s return

Departure is a turning turn for Jorgensen’s predecessor Lars Ribien Sorensen, who led Novoya for the first 16 years of the 2000s, and now the observer will join the Control Council as a full board. The Foundation said, “Experience and concepts will be valuable,” he said, supported Sorensen.

The richest charity fund in the world, despite the occupation of 28% of the share capital, manages through a stock composition leading with a two-speed shares that provides 77% recording shares in the company. His assets lost 4.8% worth last year, it is about 1.06 trillion Denmark Coner ($ 159 billion), Gates Foundation is about twice as much as possible.

“Novo has already been discouraged that the portfolio of Novo shares, which is 6.5 million pounds ($ 8.6 million), which can be discouraged,” said Mark Ellis.

But the news for many employees came as a shock.

OneclipThe senting Danish Broadcaster TV2, Jorgensen, Jorgensen, open, multi-storey central atrium’s stairs.

“You are really a beacon for all of us,” Yagub Petersen, the head of Nova’s diabetes, obesity, and Mash wrote Linkedin.

This story was first displayed Fortune.com

[ad_2]
Source link